A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity
作者: Yan LuanDafei ChaiJianjian PengShuli MaMin WangHui MaXiang LiShilong FuXiaolong PanXiaoxiao WangSongbing QinTing Xu
作者单位: 1DingFu Biotarget Co. Ltd., Suzhou, Jiangsu 215125, PR China
2Chinese Academy of Sciences Key Laboratory for Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, PR China
3Department of Radiotherapy, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, PR China
4Alphamab Co. Ltd., Suzhou, Jiangsu 215125, PR China
刊名: International Immunopharmacology, 2016, Vol.31 , pp.248-256
来源数据库: Elsevier Journal
DOI: 10.1016/j.intimp.2015.12.039
关键词: Monoclonal antibodyPD-L1B60-55TumorTherapeutic agent
原始语种摘要: Abstract(#br)Background(#br)Programmed cell death ligand-1 (PD-L1) with its receptor PD-1 pathway is overactivated in many tumors. Inhibiting the interaction of PD-L1 and PD-1 is an attractive strategy to restore tumor-specific T cell immunity for tumor therapy.(#br)Methods(#br)A fully human anti-PD-L1 monoclonal antibody (mAb) B60-55 was identified by yeast surface display. The affinity, specificity, activity, and efficacy of mAb B60-55 were investigated in vitro or in vivo.(#br)Results(#br)mAb B60-55 (purity >99%) could bind to PD-L1 that is expressed on HEK293 cells with a dissociation constant of 0.2nM, and specifically bind to human or cynomolgus macaque PD-L1 without a cross-reaction with murine PD-L1. Moreover, mAb B60-55 is an antagonistic...
全文获取路径: Elsevier  (合作)
影响因子:2.417 (2012)

  • antibody 抗体
  • monoclonal 单细胞系的
  • potent 强大的
  • targeting 导向目标
  • human 人的
  • tumor 肿胀
  • macaque 猕猴
  • lymphocyte 淋巴细胞
  • receptor 接受体
  • activity 活度